AstraZeneca sales fall25th October 2012
Latest figures from AstraZeneca show that company’s sales dropped by a bigger-than-expected 19% in the third quarter.
Analysts say that the figures underscore the challenges facing the company’s new chief executive, Pascal Soriot, who joined from Roche on October 1. AstraZeneca is faced with patent expires on once best-selling medicines and has a thin pipeline of new drugs, meaning Soriot will need to re-focus operations and step up the hunt for acquisitions. Soriot has told reporters that buying in products would be an important way of rebuilding the pipeline.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.